Reprogramming T Cells to Fight Glioblastoma

Time: 5:00 pm
day: Day Two


  • Exploiting the preferential accumulation of Tregs in the tumor by therapeutically
    altering their function
  • Discussing how the phenotype of GBM Tregs allows their selective targeting and
    reduces immune-related adverse events
  • Pre-clinical data supporting αGITR with PD1 in GBM